Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 250 entries
View as:

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM

Phase: N/A Priority: Normal
NCT ID: NCT02844309 Org: User:
Start: 05/31/16 End: 05/31/20 Due: 05/31/21

Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT05975996 Org: User:
Start: 07/10/23 End: 12/31/25 Due: 12/31/26

Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD

Phase: N/A Priority: Normal
NCT ID: NCT06698211 Org: User:
Start: 08/01/23 End: 01/01/25 Due: 01/01/26

Twice-per-weekSelinexor, 2 Days Melphalan

Phase: N/A Priority: Normal
NCT ID: NCT06613035 Org: User:
Start: 09/30/24 End: 09/30/27 Due: 09/30/28

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Phase: N/A Priority: Normal
NCT ID: NCT05846737 Org: User:
Start: 05/29/23 End: 05/01/28 Due: 05/01/29

The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT04398459 Org: User:
Start: 05/01/20 End: 06/30/25 Due: 06/30/26

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT04463953 Org: User:
Start: 05/20/20 End: 05/20/25 Due: 05/20/26

Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function

Phase: N/A Priority: Normal
NCT ID: NCT05571332 Org: User:
Start: 06/28/22 End: 06/28/24 Due: 06/28/25

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Phase: N/A Priority: Normal
NCT ID: NCT06712173 Org: User:
Start: 12/01/24 End: 03/31/26 Due: 03/31/27

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05601466 Org: User:
Start: 03/26/22 End: 04/11/23 Due: 04/11/24

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT06513234 Org: User:
Start: 07/11/24 End: 06/21/29 Due: 06/21/30

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Phase: N/A Priority: Normal
NCT ID: NCT05601830 Org: User:
Start: 10/09/22 End: 06/30/23 Due: 06/30/24

Safety and Tolerability of VGB-R04 in Patients With Haemophilia B

Phase: N/A Priority: Normal
NCT ID: NCT05152732 Org: User:
Start: 12/28/21 End: 12/31/25 Due: 12/31/26

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

Phase: N/A Priority: Normal
NCT ID: NCT06219239 Org: User:
Start: 01/04/24 End: 12/31/26 Due: 12/31/27

A Study of FVIII Gene Therapy for Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT05454774 Org: User:
Start: 07/19/22 End: 09/15/27 Due: 09/15/28

Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

Phase: N/A Priority: Normal
NCT ID: NCT06783790 Org: User:
Start: 01/20/25 End: 12/31/27 Due: 12/31/28

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06769555 Org: User:
Start: 01/01/25 End: 08/01/28 Due: 08/01/29

Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT04854889 Org: User:
Start: 04/22/21 End: 08/09/22 Due: 08/09/23

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL

Phase: N/A Priority: Normal
NCT ID: NCT06481241 Org: User:
Start: 06/10/24 End: 06/30/28 Due: 06/30/29

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

Phase: N/A Priority: Normal
NCT ID: NCT05641610 Org: User:
Start: 02/16/22 End: 12/31/28 Due: 12/31/29

Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)

Phase: N/A Priority: Normal
NCT ID: NCT06107582 Org: User:
Start: 11/01/23 End: 12/31/36 Due: 12/31/37

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05199909 Org: User:
Start: 01/25/22 End: 06/30/25 Due: 06/30/26

the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06461091 Org: User:
Start: 07/31/24 End: 04/30/25 Due: 04/30/26

γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT04028440 Org: User:
Start: 10/31/19 End: 03/31/22 Due: 03/31/23

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03031249 Org: User:
Start: 02/08/17 End: 10/15/27 Due: 10/15/28